Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1942173 | 0.94 | MAPT (0.39) | ALDH1A1KMT2ALMNAMAPTFKBP1A | |
| SCHEMBL25728480 | 0.83 | CCR2 (0.38) | ALDH1A1 | |
| SCHEMBL10125636 | 0.83 | CCR2 (0.38) | ALDH1A1 | |
| SCHEMBL799809 | 0.83 | CCR2 (0.38) | ALDH1A1 | |
| SCHEMBL3309798 | 0.79 | ALDH1A1 (0.42) | ALDH1A1KMT2ALMNAMAPTCACNA1A | |
| SCHEMBL11147800 | 0.79 | — | — | |
| SCHEMBL13314366 | 0.78 | CYP1A2 (0.40) | LMNA | |
| SCHEMBL5548236 | 0.78 | CACNA1A (0.41) | ALDH1A1KMT2ALMNAMAPTFKBP1A | |
| SCHEMBL30426031 | 0.78 | ALDH1A1 (0.37) | ALDH1A1KMT2ALMNAMAPTFKBP1A | |
| SCHEMBL12881662 | 0.75 | ALDH1A1 (0.42) | ALDH1A1KMT2AMAPTFKBP1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831164-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067401-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |